ClinicalTrials.gg
CompletedNCT00775203Updated Apr 27, 2012Results posted

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

A Phase 3 interventional study of Trazodone Hydrochloride (HCl) Extended-Release Tablets and Placebo in Major Depressive Disorder, sponsored by Labopharm Inc.. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-27.

Sponsored by Labopharm Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
185th of 1,323
412 · median 70
Started
2007
with 49 others
Phase 3
240 of 1,500
21 open now
Registered
315th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 185th largest by enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2007, is one of 240 in phase 3, and was the 315th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).

Read the detailed description

This two-arm, multicentre, randomized, placebo-controlled, double-blind, parallel-design study consisted of a baseline phase (screening and wash-out) and a double-blind randomized phase (randomization to Trazodone Contramid® OAD or placebo). The total study duration including wash-out of prohibited medications was approximately 11 weeks; the total duration of the randomized phase was 8 weeks (titration: 2 weeks + treatment: 6 weeks).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Unipolar
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females.
  • Aged 18 years or older.
  • Fulfills , 4th Edition (DSM-IV) criteria for Unipolar Major Depressive Disorder (MDD) (Axis I) as confirmed by the Mini-International Neuropsychiatric Interview (MINI).
  • The primary DSM-IV Axis I diagnosis should be MDD (296.22, 296.23, 296.32, 296.33); any subject meeting criteria for another, non excluded Axis I disorder, must demonstrate MDD as the primary disorder.
  • The current episode of MDD should have lasted for a minimum of 1 month, whether the patient has been diagnosed with one single or recurrent episodes.
  • Presence of dysphoria for most days over the past four weeks.
  • Montgomery-Åsberg Depression Rating Scale (MADRS) total score of at least 26 at screening and baseline.
  • Oral and written language comprehension at a level sufficient to comply with the protocol and to complete study-related materials.
  • Sign and date a written Form (ICF) approved by a Research Ethic Board (REB) which has also been signed and dated by the Investigator prior to study participation.

Exclusion criteria

Exclusion Criteria:

  • Major Depressive Disorder Specifiers: [a] With Catatonic Features; [b] With Postpartum Onset; [c] With Seasonal Pattern;
  • Presence of any of the following DSM-IV Axis I disorders: generalized anxiety disorder, panic disorder, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, eating disorder, bipolar disorder, alcohol/substance abuse or dependence (caffeine and nicotine allowed), any psychotic disorder.
  • Depression secondary to stroke, cancer or other severe medical illnesses.
  • Positive urine drug screen at screening visit.
  • History or present condition of any DSM-IV Axis II disorder.
  • History of treatment major depressive episodes defined as incomplete or no therapeutic response to two prior courses of at least one month of conventional antidepressant drug treatment in adequate dosages.
  • Currently in psychotherapy (at least one session in the past month with a plan for continuing) with a licensed/registered/certified mental health provider, marriage counselor, or family therapist.
  • Meet criteria for high suicide risk on the MINI suicide scale, or in the opinion of the investigator is inappropriate for the trial due to suicidal or homicidal potential.
  • Require hospitalization for treatment of the current episode of depression.
  • Uncorrected hypo- or hyperthyroidism.
  • A history of seizures other than pediatric febrile seizure.
  • A history of cardiac arrythmias requiring therapy.
  • A history of myocardial infarction within 1 year before screening.
  • Clinically significant abnormal findings of Electrocardiography (), laboratory parameters.
  • Unwilling to discontinue use of any antidepressants, including herbal remedies, for a minimum of 5 drug half-lives prior to screening.
  • Unwilling to discontinue use of prohibited medications for a minimum of 5 drug half-lives prior to screening.
  • Treatment within the last 3 weeks with Monoamine Oxidase (MAO) inhibitors.
  • Use of the following concomitant treatment during the study:

    • medications causing (e.g. amiodarone, droperidol, erythromycin).
    • medications causing PR prolongation (e.g. digoxin).
    • Anti -psychotics (e.g. haloperidol).
    • protease inhibitors such as ritonavir and indinavir.
  • Hormonal treatment (e.g. estrogen, oral ) which has started within 3 months of study entry.
  • Treatment with another agent within the last 30 days.
  • Known and documented allergy to trazodone or any structurally similar drugs.
  • Previous failure of treatment with trazodone, or previous discontinuation of treatment with trazodone due to Adverse Events.
  • Bowel disease causing malabsorption.
  • Serious, unstable illnesses during the 3 months before screening including but not limited to: hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic or hematological disease.
  • Pregnant or lactating, or is of and not willing to use an approved method of contraception.
  • Significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range.
  • Significant renal disease, defined as Blood Urea Nitrogen (BUN) and/or creatinine >3 times the upper boundary of the normal range clearance.
  • Any other condition that, in the opinion of the investigators, would adversely affect the patient's ability to complete the study or its measures.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
412 participants (actual)

Study arms

  • Experimental
    Trazodone Contramid Once A Day (OAD)

    Drug: Trazodone Hydrochloride (HCl) Extended-Release Tablets

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline

    The Hamilton Depression Rating Scale 17 items \[HAMD-17\] is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill).

    Time frame: Baseline to Week 8

Secondary outcomes

  1. HAMD-17 Responders at Each Visit

    Number of patients who show a response (defined as at least a 50% reduction from baseline in HAMD-17 score) at each post-baseline visit.

    Time frame: Weeks 1, 2, 3, 4, 6, 8

  2. HAMD-17 Remitters at Each Visit

    Number of patients who are remitters (defined as patients who achieved a HAMD-17 total score ≤7) at each post-baseline visit.

    Time frame: Weeks 1, 2, 3, 4, 6, 8

  3. Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit

    Change from baseline in the HAMD-17, item 1: Depressed Mood item, at each post-baseline visit. The Depressed Mood item is rated on a 5-point scale ranging from rating of 0=absent; to 4=very severe.

    Time frame: Baseline to Weeks 1, 2, 3, 4, 6, 8

  4. Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10 item clinician-administered depression rating scale. The 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) are rated on a scale ranging from 0 (low severity/difficulty) to 6 (high severity/difficulty) with anchors at 2-point intervals. The overall total score range is from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline to Week 8

  5. Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit

    The CGI-Severity (CGI-S) consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

    Time frame: Baseline to Weeks 1, 2, 3, 4, 6, 8

  6. Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit

    The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse.

    Time frame: Week 8

  7. Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit

    The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.

    Time frame: Week 8

  8. Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit

    Patients were responders if the CGI-I rating was "Much Improved" or "Very Much Improved". The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.

    Time frame: Week 8

  9. Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit

    Patients were responders if the PGI-I rating was "Much Improved" or "Very Much Improved". The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.

    Time frame: Week 8

  10. Overall Quality of Sleep at Each Visit

    Overall Quality of Sleep was measured on a 4-point rating scale ranging from 1 = very poor to 4 = excellent in response to the question: "Since the last study visit, how would you rate the overall quality of your sleep?".

    Time frame: Weeks 1, 2, 3, 4, 6, 8

  11. Trouble Falling Asleep at Each Visit

    Trouble Falling Asleep was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit, how often did you experience trouble falling asleep?".

    Time frame: Weeks 1, 2, 3, 4, 6, 8

  12. Awakening During the Night at Each Visit

    Awakening during the night was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit did you awaken during the night?".

    Time frame: Weeks 1, 2, 3, 4, 6, 8

  13. Discontinuation Due to Lack of Efficacy

    Number of patients who discontinued due to lack of efficacy during the whole study period (8 weeks).

    Time frame: Baseline to Week 8

07

Results

Posted Apr 7, 2010

Participant flow

Participant flow — Overall Study
MilestoneTrazodone Contramid OADPlacebo
Started206206
Received study medication202204
Completed144163
Not completed6243
Withdrew: Adverse event256
Withdrew: Lack of efficacy89
Withdrew: Withdrawal by subject119
Withdrew: Lost to follow-up1115
Withdrew: Administrative reason20
Withdrew: Noncompliance42
Withdrew: Protocol violation01
Withdrew: Entered other study10
Withdrew: Physician decision01

Outcome measures

PrimaryChange in Hamilton Depression Scale (HAMD-17) Total Score From Baseline

The Hamilton Depression Rating Scale 17 items \[HAMD-17\] is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17score ranges from 0 (not ill) to 52 (severely ill).

Time frame:
Baseline to Week 8
Reported as:
Mean · Points on HAMD-17 scale
Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline
Points on HAMD-17 scaleTrazodone Contramid OADPlacebo
Baseline23.2 ± 4.1622.4 ± 4.43
Week 8 or LOCF11.8 ± 7.9913.2 ± 8.06
Change from baseline-11.4 ± 8.20-9.3 ± 7.94
Statistical analysis
  • Trazodone Contramid OAD vs Placebo · ANCOVA · p = 0.0119ANCOVA with treatment and study center as categorical factors and HAMD-17 baseline as covariate.
SecondaryHAMD-17 Responders at Each Visit

Number of patients who show a response (defined as at least a 50% reduction from baseline in HAMD-17 score) at each post-baseline visit.

Time frame:
Weeks 1, 2, 3, 4, 6, 8
Reported as:
Number · Participants
HAMD-17 Responders at Each Visit
ParticipantsTrazodone Contramid OADPlacebo
≥50% reduction in HAMD-17 at Week 1 (n=197, n=199)2519
≥50% reduction in HAMD-17 at Week 2 (n=201, n=203)6341
≥50% reduction in HAMD-17 at Week 3 (n=202, n=204)8953
≥50% reduction in HAMD-17 at Week 4 (n=202, n=204)9574
≥50% reduction in HAMD-17 at Week 6 (n=202, n=204)10081
≥50% reduction in HAMD-17 at Week 8 (n=202, n=204)10984
SecondaryHAMD-17 Remitters at Each Visit

Number of patients who are remitters (defined as patients who achieved a HAMD-17 total score ≤7) at each post-baseline visit.

Time frame:
Weeks 1, 2, 3, 4, 6, 8
Reported as:
Number · Participants
HAMD-17 Remitters at Each Visit
ParticipantsTrazodone Contramid OADPlacebo
Number of remitters at Week 1 (n=197, n=199)109
Number of remitters at Week 2 (n=201, n=203)2924
Number of remitters at Week 3 (n=202, n=204)5132
Number of remitters at Week 4 (n=202, n=204)6143
Number of remitters at Week 6 (n=202, n=204)6647
Number of remitters at Week 8 (n=202, n=204)7265
SecondaryChange in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit

Change from baseline in the HAMD-17, item 1: Depressed Mood item, at each post-baseline visit. The Depressed Mood item is rated on a 5-point scale ranging from rating of 0=absent; to 4=very severe.

Time frame:
Baseline to Weeks 1, 2, 3, 4, 6, 8
Reported as:
Mean · Points on the HAMD scale
Change in HAMD-17 Depressed Mood Item (Item 1) Score From Baseline to Each Visit
Points on the HAMD scaleTrazodone Contramid OADPlacebo
Change in score at Week 1 (n=197, n=199)-0.7 ± 0.89-0.5 ± 0.74
Change in score at Week 2 (n=201, n=203)-1.1 ± 1.13-0.8 ± 0.95
Change in score at Week 3 (n=202, n=204)-1.4 ± 1.18-1.0 ± 1.08
Change in score at Week 4 (n=202, n=204)-1.5 ± 1.21-1.2 ± 1.12
Change in score at Week 6 (n=202, n=204)-1.5 ± 1.18-1.3 ± 1.15
Change in score at Week 8 (n=202, n=204)-1.6 ± 1.29-1.3 ± 1.22
SecondaryChange in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10 item clinician-administered depression rating scale. The 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts) are rated on a scale ranging from 0 (low severity/difficulty) to 6 (high severity/difficulty) with anchors at 2-point intervals. The overall total score range is from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline to Week 8
Reported as:
Mean · Units on MADRS scale
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score From Baseline
Units on MADRS scaleTrazodone Contramid OADPlacebo
Baseline (n=202, n=204)32.6 ± 4.0731.9 ± 4.33
Week 8 (n=178, n=182)16.0 ± 11.2417.7 ± 11.62
Change from baseline (n=178, n=182)-16.6 ± 11.27-14.1 ± 11.27
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit

The CGI-Severity (CGI-S) consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

Time frame:
Baseline to Weeks 1, 2, 3, 4, 6, 8
Reported as:
Mean · Units on CGI-S scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S) to Each Visit
Units on CGI-S scaleTrazodone Contramid OADPlacebo
Change in CGI-S score at Week 1 (n=197, n=199)-0.6 ± 0.72-0.5 ± 0.75
Change in CGI-S score at Week 2 (n=201, n=203)-1.0 ± 1.02-0.8 ± 0.98
Change in CGI-S score at Week 3 (n=202, n=204)-1.4 ± 1.16-1.1 ± 1.12
Change in CGI-S score at Week 4 (n=202, n=204)-1.6 ± 1.22-1.3 ± 1.17
Change in CGI-S score at Week 6 (n=202, n=204)-1.7 ± 1.24-1.4 ± 1.24
Change in CGI-S score at Week 8 (n=202, n=204)-1.7 ± 1.36-1.4 ± 1.37
SecondaryClinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit

The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse.

Time frame:
Week 8
Reported as:
Mean · Units on the CGI-I scale
Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit
Units on the CGI-I scaleTrazodone Contramid OADPlacebo
Clinical Global Impression - Improvement of Illness (CGI-I) Score at Last Study Visit2.4 ± 1.232.5 ± 1.32
SecondaryPatient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit

The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.

Time frame:
Week 8
Reported as:
Mean · Units on PGI-I scale
Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit
Units on PGI-I scaleTrazodone Contramid OADPlacebo
Patient Global Impression - Improvement of Illness (PGI-I) Score at Last Study Visit2.6 ± 1.192.8 ± 1.35
SecondaryClinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit

Patients were responders if the CGI-I rating was "Much Improved" or "Very Much Improved". The CGI-Improvement of Illness (CGI-I) consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.

Time frame:
Week 8
Reported as:
Number · participants
Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit
participantsTrazodone Contramid OADPlacebo
Clinical Global Impression - Improvement of Illness (CGI-I) Responders at Last Study Visit9689
SecondaryPatient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit

Patients were responders if the PGI-I rating was "Much Improved" or "Very Much Improved". The PGI-Improvement of Illness (PGI-I) consists of one question for the patient: "Since the start of the study, my overall status with regard to depression is?" which is rated on the following seven-point scale 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse. Results are expressed in number of patients.

Time frame:
Week 8
Reported as:
Number · participants
Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit
participantsTrazodone Contramid OADPlacebo
Patient Global Impression - Improvement of Illness (PGI-I) Responders at Last Study Visit9080
SecondaryOverall Quality of Sleep at Each Visit

Overall Quality of Sleep was measured on a 4-point rating scale ranging from 1 = very poor to 4 = excellent in response to the question: "Since the last study visit, how would you rate the overall quality of your sleep?".

Time frame:
Weeks 1, 2, 3, 4, 6, 8
Reported as:
Mean · Points on a scale
Overall Quality of Sleep at Each Visit
Points on a scaleTrazodone Contramid OADPlacebo
Score at Baseline (n=202, n=204)1.6 ± 0.651.6 ± 0.70
Score at Week 1 (n=196, n=199)0.7 ± 0.900.4 ± 0.83
Score at Week 2 (n=200, n=203)0.8 ± 0.970.7 ± 0.99
Score at Week 3 (n=201, n=204)0.9 ± 1.000.7 ± 1.00
Score at Week 4 (n=201, n=204)1.0 ± 1.020.7 ± 1.02
Score at Week 6 (n=201, n=204)1.0 ± 1.010.9 ± 1.04
Score at Week 8 (n=201, n=204)1.0 ± 1.050.8 ± 1.10
SecondaryTrouble Falling Asleep at Each Visit

Trouble Falling Asleep was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit, how often did you experience trouble falling asleep?".

Time frame:
Weeks 1, 2, 3, 4, 6, 8
Reported as:
Mean · Units on a scale
Trouble Falling Asleep at Each Visit
Units on a scaleTrazodone Contramid OADPlacebo
Score at Baseline (n=202, n=204)3.0 ± 0.862.9 ± 0.91
Score at Week 1 (n=196, n=199)2.5 ± 1.022.6 ± 0.98
Score at Week 2 (n=200, n=203)2.3 ± 0.932.5 ± 0.96
Score at Week 3 (n=201, n=204)2.2 ± 0.902.3 ± 0.99
Score at Week 4 (n=201, n=204)2.1 ± 0.892.3 ± 0.95
Score at Week 6 (n=201, n=204)2.1 ± 0.892.3 ± 0.95
Score at Week 8 (n=201, n=204)2.1 ± 0.852.3 ± 0.95
SecondaryAwakening During the Night at Each Visit

Awakening during the night was measured on a 4-point rating scale ranging from 1 = never to 4 = always in response to the question: "Since the last study visit did you awaken during the night?".

Time frame:
Weeks 1, 2, 3, 4, 6, 8
Reported as:
Mean · Units on a scale
Awakening During the Night at Each Visit
Units on a scaleTrazodone Contramid OADPlacebo
Score at Baseline (n=202, n=204)3.2 ± 0.783.2 ± 0.78
Score at Week 1 (n=196, n=199)2.4 ± 0.962.7 ± 0.85
Score at Week 2 (n=200, n=203)2.4 ± 0.942.5 ± 0.92
Score at Week 3 (n=201, n=204)2.2 ± 0.912.6 ± 0.90
Score at Week 4 (n=201, n=204)2.2 ± 0.892.6 ± 0.93
Score at Week 6 (n=201, n=204)2.2 ± 0.942.5 ± 0.95
Score at Week 8 (n=201, n=204)2.2 ± 0.892.5 ± 0.95
SecondaryDiscontinuation Due to Lack of Efficacy

Number of patients who discontinued due to lack of efficacy during the whole study period (8 weeks).

Time frame:
Baseline to Week 8
Reported as:
Number · participants
Discontinuation Due to Lack of Efficacy
participantsTrazodone Contramid OADPlacebo
Discontinuation Due to Lack of Efficacy89

Adverse events

Collected over 8 weeks (plus an additional 30 days for SAEs only). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trazodone Contramid OAD—4/202 (2%)168/202 (83.2%)
Placebo—2/204 (1%)122/204 (59.8%)
Most frequent serious events
Most frequent serious events
EventTrazodone Contramid OADPlacebo
Abdominal painGastrointestinal disorders1/2020/204
Duodenal ulcerGastrointestinal disorders1/2020/204
GastritisGastrointestinal disorders1/2020/204
Staphylococcal sepsisInfections and infestations1/2020/204
Viral pericarditisInfections and infestations1/2020/204
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2020/204
DeathGeneral disorders0/2021/204
Suicide attemptPsychiatric disorders0/2021/204
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTrazodone Contramid OADPlacebo
HeadacheNervous system disorders67/20255/204
SomnolenceNervous system disorders63/20232/204
Dry mouthGastrointestinal disorders51/20226/204
DizzinessNervous system disorders50/20225/204
NauseaGastrointestinal disorders42/20226/204
SedationNervous system disorders34/2027/204
FatigueGeneral disorders30/20217/204
DiarrheaGastrointestinal disorders19/20223/204
ConstipationGastrointestinal disorders16/2024/204
Vision blurredEye disorders11/2020/204

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Trazodone Contramid OADPlaceboTotal
<=18 years022
Between 18 and 65 years193186379
>=65 years91625
Age Continuous
Age Continuous(years)Trazodone Contramid OADPlaceboTotal
Mean43.8 ± 12.8344.0 ± 13.4543.9 ± 13.12
Sex: Female, Male
Sex: Female, Male(Participants)Trazodone Contramid OADPlaceboTotal
Female129131260
Male7373146
Region of Enrollment
Region of Enrollment(participants)Trazodone Contramid OADPlaceboTotal
United States169166335
Canada333871
08

Study locations

37 sites
  • Birmingham, Alabama 35216, United States
  • Mesa, Arizona 85206-4616, United States
  • Beverly Hills, California 90210, United States
  • Burbank, California 91506, United States
  • San Diego, California 92108, United States
  • Denver, Colorado 80212, United States
  • Gainesville, Florida 32607, United States
  • Hialeah, Florida 33013, United States
  • Jacksonville, Florida 32216, United States
  • Orlando, Florida 32806, United States
  • Tampa, Florida 33613, United States
  • Atlanta, Georgia 30328, United States
  • Marietta, Georgia 30060, United States
  • Smyrna, Georgia 30080, United States
  • Libertyville, Illinois 60048, United States
  • Indianapolis, Indiana 46202, United States
  • Overland Park, Kansas 66212, United States
  • Clementon, New Jersey 08021, United States
  • Brooklyn, New York 11235, United States
  • New York, New York 10021, United States
  • New-York, New York 10021, United States
  • Beachwood, Ohio 44122, United States
  • Cincinnati, Ohio 45242, United States
  • Dayton, Ohio 45408, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Philadelphia, Pennsylvania 19149, United States
  • Bellaire, Texas 77401, United States
  • San Antonio, Texas 78229, United States
  • Woodstock, Vermont 05091, United States
  • Kelowna, British Columbia V1Y2H4, Canada
  • Penticton, British Columbia V2A5C8, Canada
  • Mount Pearl, Newfoundland and Labrador A1N1W7, Canada
  • Hamilton, Ontario L8L5G8, Canada
  • Oakville, Ontario L6J3J4, Canada
  • Gatineau, Quebec J9A1K7, Canada
  • Saint-Leonard, Quebec H1S3A9, Canada
  • Sherbrooke, Quebec J1H4J6, Canada
09

References and documents

Publications

  • Sheehan DV, Croft HA, Gossen ER, Levitt RJ, Brulle C, Bouchard S, Rozova A. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry (Edgmont). 2009 May;6(5):20-33. PubMed 19724732 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 2 years 5 months after primary completion. A results delay was requested in Mar 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2008
First posted
Oct 20, 2008
Start
Jun 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results delay requested
Mar 16, 2009
Results first posted
Apr 7, 2010
Last update
Apr 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00775203
Lead sponsor
Labopharm Inc.
First posted
Oct 20, 2008
Start date
Jun 2007
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Apr 7, 2010
Last update
Apr 27, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion